Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 3/20 | 0.44 |
| ▸ | GHSR | Q92847 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4587279 | 0.98 | CTRB1 (0.44) | CTRB1GHSRHDAC3HDAC4HDAC1 | |
| SCHEMBL5598606 | 0.91 | MME (0.46) | CTRB1 | |
| SCHEMBL31184506 | 0.91 | MME (0.46) | CTRB1 | |
| SCHEMBL5598613 | 0.91 | MME (0.46) | CTRB1 | |
| SCHEMBL4587272 | 0.90 | MME (0.46) | CTRB1 | |
| SCHEMBL2241975 | 0.90 | MME (0.46) | CTRB1 | |
| SCHEMBL2813160 | 0.89 | CTRB1 (0.33) | CTRB1 | |
| SCHEMBL2244570 | 0.88 | CTSC (0.40) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL4587808 | 0.87 | CTRB1 (0.33) | CTRB1 | |
| SCHEMBL4589444 | 0.86 | CTSC (0.40) | HDAC3HDAC4HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110206790-A1 | Antimicrobial Foamable Soaps | OHSO CLEAN, INC | 2011-08-25 | — | — | US | disclosed |
| EP-2350252-A2 | ANTIMICROBIAL FOAMABLE SOAPS | Ohso Clean, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20100249042-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYELASHES AND EYEBROWS | PROCYTE CORPORATION (US) | 2010-09-30 | — | — | US | disclosed |
| WO-2010059366-A2 | ANTIMICROBIAL FOAMABLE SOAPS | OHSO CLEAN, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| EP-1613302-B1 | PRESERVED AND STABLE COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND METHODS RELATED THERETO | PROCYTE CORP (US) | 2009-12-23 | — | — | EP | disclosed |
| US-7179789-B2 | Compositions and methods for treatment of rosacea | PROCYTE CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
| US-7128923-B2 | Preserved and stable compositions containing peptide copper complexes and method related thereto | PROCYTE CORPORATION (US) | 2006-10-31 | — | — | US | disclosed |
| US-20060052287-A1 | Polyethylene glycol - peptide copper complexes and compositions and methods related thereto | PROCYTE CORPORATION (US) | 2006-03-09 | — | — | US | disclosed |
| US-20050209130-A1 | Compositions and methods for treatment of rosacea | PROCYTE CORPORATION (US) | 2005-09-22 | — | — | US | disclosed |
| US-20050197282-A1 | for topical administration of peptide copper complex with corticosteroids, coal tar, anthralin, calcipotriene, and tazarotene; dermatology; cosmetics | PROCYTE CORPORATION (US) | 2005-09-08 | — | — | US | disclosed |
| US-6927205-B2 | Compositions and methods for treatment of psoriasis | PROCYTE CORPORATION (US) | 2005-08-09 | — | — | US | disclosed |
| US-6927206-B2 | Compositions and methods for treatment of rosacea | PROCYTE CORPORATION (US) | 2005-08-09 | — | — | US | disclosed |
| EP-0765152-B1 | STIMULATION OF HAIR GROWTH BY PEPTIDE-COPPER COMPLEXES | PROCYTE CORP (US) | 2001-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209130-A1 | Compositions and methods for treatment of rosacea | CUTA, AOC1, RCN1 | CTRB1 6/4885GHSR 759/4885HDAC3 4165/4885 |
| US-20060052287-A1 | Polyethylene glycol - peptide copper complexes and compositions and methods related thereto | NGLY1, CUTA, TFRC | CTRB1 90/4885GHSR 854/4885HDAC3 4836/4885 |
| US-20100249042-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYELASHES AND EYEBROWS | CUTA, TYR, EYA3 | CTRB1 43/4885GHSR 529/4885HDAC3 4296/4885 |
| US-20050197282-A1 | for topical administration of peptide copper complex with corticosteroids, coal tar, anthralin, calcipotriene, and tazarotene; dermatology; cosmetics | PTH1R, TSLP, CYP27B1 | CTRB1 104/4885GHSR 1509/4885HDAC3 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.